Guotong Man, MD, PhD

21 Littell Road, APT  3
Brookline, MA 02446
617-602-5581   
graceman_usa@yahoo.com

PROFESSIONAL SUMMARY
MD, PhD level medical scientist possesses a robust knowledge of molecular & cellular biology, immunology, histology, etc, with more than 15 years research experience. Experienced in project management, supervising and administrating research team; Deeply participated in research areas such as transplantation, type 1 and type 2 diabetes, biliary and pancreatic diseases. Recently engaged in gastroenterological physiology and pathology, focused on understanding mechanisms of weight loss and type 2 diabetes resolution after various bariatric surgeries; Well trained and skillful with variety of methodologies of immunology, molecular and cellular biology, histology,  humanized mice models, transplantation & xenotransplantation, such as culturing human, pig and rodents T cells, dendritic cells, macrophages, NK T and NK cells, endothelial cells, islets of Langerhans; deft in ELISA, ELISPOT, FACS, MACS, FPLC, WST-1, MLR, MTT, FISH, antibody production and purification;  tissue embedding and sectioning, immunohistochemistry and immunofluorescence; Proven ability to design, produce, develop, and carry out comprehensive research projects, with records of being dexterous in grant writing. Adroit  in rodent surgeries such as bariatric surgical animal models, including RYGB, duodenal-jejunal bypass surgery(DJB), biliopancreatic diversion(BPD), Ileal interposition, rat Brown Fat Tissue stimulation models; islets isolation and transplantation in rodents, xenotransplantation models; mouse bone marrow transplantation. Expert in managing and handling transgenic mouse models, 
Researching  experience
•	GI Metabolism Laboratory, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA                                                    2012-present
Surgical Research Specialist and Leading Member:

•	Developing new and refining existing bariatric surgical models in rodents;
•	Utilizing existing and newly-developed rodent (rat and mouse) models of bariatric surgical procedures to examine the GI regulation of food intake, energy expenditure and glucose homeostasis.
•	Developing and maintaining standard operating procedures for surgical procedures and post-operative protocols. 
•	Supervising and mentoring team of surgical and veterinary technicians, teaching surgical procedures to new laboratory members and visiting scientists.  
•	Developed  and modified bariatric animal models(rat and mouse) including RYGB, duodenal-jejunal bypass surgery(DJB), biliopancreatic diversion(BPD), Ileal interposition, rat Brown Fat Tissue stimulation models, etc. 

•	Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA                                                                                                                2011-2011
Research Fellow:

Collected data from adult critical ill patients hospitalized in Intensive care units in Brigham’s and Women’s Hospital with various diseases. All these patients were administered with a period of Total Parenteral Nutrition. During this period, these patients were complicated by bloodstream infection. There is a paucity of evidence-based recommendations from national and international societies regarding the practice of TPN administration during septicemia, regardless of etiology. For addressing the issue of appropriate TPN management in septicemic patients, we conducted a retrospective analysis of TPN receiving patients who developed septicemia.  Patients were grouped into TPN continued versus TPN stopped within 48 hours of septicemia. Our data showed TPN receiving patients who continued to receive TPN after septicemia had no difference in mortality or septicemia recurrence but had significantly longer duration of hospitalization. 

•	Diabetes Institutes, Medicine Department, Massachusetts General Hospital, Harvard University, Boston, USA                                                                                2007-2010
Research Fellow and Leading Member:
	Developed humanized mouse using NOD/SCID expressing HLA-A2 to detect defective antigen presentation in NOD mice and to define this process as a central cause of autoimmunity. This is a major pathway for T cell education and prevention of autoimmunity. Immunobiochemistry Histology (Frozen Tissue and Paraffin Embedded Tissue) was intensively employed in this study. 
	Developed comprehensive immunobiology assay to detect autoimmune CD8 & CD4 T-cells in peripheral blood of Type I diabetic patients by FACS, WST, ELISA, ELISPOT, RT-PCR, PCR, SSCP, DGGE, either with or without in vitro perturbations with such stimulants as cytokines or receptor agonists.
	The lymphocytes have been separated from the blood samples and the cells have been injected into either humanized or non-humanized mouse models to further analyze and identify the autoimmune T cells.
	Involved in two clinical trials.

•	Transplantation Biology Research Center (TBRC), Surgery Department Massachusetts General Hospital, Harvard Medical School, Harvard University, USA  
                                                                                                                                  2006-2007 
Research Fellow and Leading Member:
	Developed humanized mouse models with a functional human immune system for the study of human immune function in vivo. These humanized mice show normal human thymopoiesis, systemic repopulation with multilineages of human lymphohematopoietic cells (e.g., T, B and dendritic cells), formation of secondary lymphoid organs with normal architecture, and strong antigen-specific T cell and antibody responses upon immunization.
	Developed mixed chimerism in humanized NOD/SCID mice to induce human T and B cell tolerance to pig islets. Developed the protocols to isolate, purify, identify and culture the islets-like cell clusters from fetal pigs, and islets from newborn pigs.
 	Devised strategies for cloning pig CD47 cDNA from pig peripheral blood mononuclear cells. Designed the sequence of the oligonucleotide primers, prepared RNA from pig peripheral blood mononuclear cells, synthesized pig CD47 cDNA by RT-PCR. Subcloned this pig CD47 cDNA into plasmid pEF-BOS-Cd4d3+Bio. Constructed expressing plasmid pEF-BOS-pigCd47-Cd4d3+Bio, identified and verified the right clone by restriction endonuclease digestion and DNA sequencing. 
	Discovered:  ⑴Treatment with adenosine receptor A2a agonist, ATL146e, moderately increased porcine hematopoietic engraftment in C.B-17 SCID mice, presumably through inhibit macrophage activation. ⑵ Failure to prevent clearance of CD47 KO cells in WT (Wild Type) mice suggests that ATL146e is not efficient in inhibiting macrophage phagocytic activity.

•	Diabetes Institutes, Medicine Department, Massachusetts General Hospital, Harvard Medical School, Harvard University,  Boston, USA                                                   2004-2006 

Postdoctoral Research fellow and Leading Member:
	Established several diabetic mouse models such as C57BL/6J and BALB/c strain which induced by injection of streptozotocin (STZ), spontaneous diabetic mouse model of NOD/Lt strain and diabetic mouse model of NOD/Lt strain induced by injection of cyclophosphoamide (CY).
	Developed and perfected the practicable protocol to isolate and purify high-quality islets from several strains of mice, such as C57BL/6J, BALB/c and NOD/SCID. As less as 300 islets translated into diabetic mouse could reverse the hyperglycemia (As high as 800-1, 000 islets are demanded according to the literature). 
	Isolated and cultured myeloid Dendritic cells, NKT cells from bone marrow, spleen, liver and especially from pancreatic lymphnodes of mouse. Isolated and cultured myeloid Dendritic cells and NKT cells from Human peripheral blood. Produced and purified mouse anti human CD154 monoclonal antibodies from supernatant of cultured hybridoma cells by comprehensively employing several advanced techniques such as affinity chromatography and FPLC. Designed comprehensive experiments by using human NK (nature killer) cells as an instrument to identify and verify the authenticity and the function of the anti-human NKG2D monoclonal antibody. 
	Based upon above mentioned mouse models, Dendritic cells, NKT cells, anti-human CD154 antibodies and anti NKG2D antibodies, combining other sophisticated modern scientific methods such as FACS analysis, ELISA analysis, Pathologic and Immunopathologic analysis, carried out experiments to illuminate the rationale by which CD1d-restricted (iNKT) cells regulate the development of tolerogenic DC in the NOD mouse. Thereby, strategies for using DC and iNKT cells as adjutants to enhance islet of Langerhans allograft survival were further optimized.

•	Surgery Department, Third Hospital of Beijing University, Health Science Center, Beijing University, Beijing, China                                                                              1998-2004

Research fellow/ Associate Professor:
•	Developed strategies to obtain potential target genes of HLA (human lymphocyte antigen) that can be used to inhibit cell-mediated immunity in pig-to-human xenotransplantation, meanwhile, cytotoxicity of CTL cells is not activated if expressing mutated HLA molecules on the membrane of pig cells through genetic maneuver. An in-vitro model was established by expressing wild-type and/or mutated HLA molecules on a clonal porcine B-lymphoblastoid cell line (LCL 13271.10) through transgenic methods.For unveiling the mechanisms underlying so-called Biliary-cardiac syndrome,
•	Established several very critical in vitro and in vitro models including:  ⑴ Isolated rat heart perfusion model. ⑵ In vitro experimental models of cultured gallbladder smooth muscle, bile duct smooth muscle, and Oddi sphincter smooth muscle. ⑶ In vitro experimental models of cardiac smooth muscle and vascular smooth muscle (coronary vascular smooth muscle bundles of rabbit). ⑷ Cholesterol gallstone animal model of Hamster.
•	Developed a transgenic mice model for further heterologous transplantation study. Human CD59 cDNA was used as a targeting gene under the control of OMT (ovine metallothionein) promoter, and GFP (green fluorescent protein) as a marker for gene expression under the control of CMV( cytomegalovirus) promoter. Genotyping of transgenic founders was performed on tail genomic DNA by polymerase chain reaction (PCR) and Southern blot analysis.
•	Conducted a nation-wide clinical trial as a co-investigator in China from 2002 to 2003. 
EDUCATION
PhD, Biliary Tract and Liver Disease, Third Hospital of Beijing University, Health Science Center, Beijing University, Beijing, China                                                                        1998
Research – “The experimental studies of inhibiting the hyperacute rejection of the pig to human xenotransplantion by transferring the human CD59 cDNA in vitro models”
MS, Biliary Tract and Liver Disease, School of Medicine, Shanghai Jiao Tong University (Originally Shanghai Second Medical University), Shanghai, China                                 1993
Research –“Investigation of the function of gallbladder in gallstone disease”

MD, Medicine, Medical college of Soochow University (Originally Suzhou Medical College), Suzhou (Soochow), China                                                                                             1987
Publications
1.	Man Guotong, Zhang Tonglin, Zhou Xiaosi. In vitro model of hyperacute rejections in swine to human xenotransplantation. Chin Surg, January 2000, 38(1):44-46. 
2.	Man Guotong, Zhang Tonglin, Zhou Xiaosi. The experimental study of transfecting the human CD59 gene into the rat aortic smooth muscle cells. Journal of Beijing Medicinal University, October 2000, 32(5):419-422.
3.	Man Guotong, Zhang Tonglin, Zhou Xiaosi. Improvement of the techniques of culturing and purifying pig aortic endothelial cells, human umbilical vein endothelial cells, pig and rat aortic smooth muscle cells. Chinese Journal of Histochemistry and Cytochemistry, 2001, 10(2)128-133. 
4.	Man Guotong, Zhang Tonglin, Dang Yongkang, Zhou Xiaosi. Experience of 35 cases of blunt abdominal truma with severe injuries of gastrointestinal tract.. Chinese Journal of Traumatology, 2001, 17(4) 243-245.
5.	Li Zhiwei, Hong Zhixian, Sun wenbing, Zhang Tonglin, Man Guotong. Animal model for heterologous transplantation-generating of transgenic mice that expresses hCD59 CDNA. Journal of Shanxi Medical University, August 2003, 34(4):298-301. 
6.	Li Zhiwei，Chang Weihua，Sun Wenbing， Wang Gang，Man Guotong. Surgical management of cholelithiasis patients with cirrhosis and portal hypertension: a report of 34 cases. Chinese Journal of General Surgery, 2004, 117(1), 40-45.
7.	Zhou Xiaosi, Zhou Shenquan, Dong Jiahong, Wu Weize, Zhang Yangde, Zhang Tonglin, Zen Zhong, Li Nianfeng, Man Guotong. Comparison of efficacy between ceftriaxone and cefoperazone plus sulbactam in peri-operative treatment of acute suppurative cholangitis. National Medical Journal of China.2004, 84(22), 1879-1882.
8.	Vihas Patel MD; Guotong Man MD, PhD; Caryn Domenici Belisle RPh; Stanley Ashley MD. Parenteral nutrition infusion during septicemia. International Surgical Week/ISW2011, Yokohama,Japan, August, 2011. 
9.	Denise L DL Faustman, Limei L Wang, Yoshiaki Y Okubo, Douglas D Burger, Liqin L Ban, Guotong G Man, Hui H Zheng, David D Schoenfeld, Richard R Pompei, Joseph J Avruch, David M DM Nathan. Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One 7(8):e41756 (2012).
10.	Vihas Patel, MD, Guotong Man, MD, PhD, Caryn Domenici Belisle, RPh, Stanley Ashley, MD. Total Parenteral Nutrition Infusion During Septicemia is Associated with Longer Hospitalization.. The Massachusetts Chapter of the American College of Surgeons (MCACS), 2013.
11.	Guotong Man, M.D. , Ph.D., Limei Wang, Ph.D., Yoshiaki Okubo, M.D., , Liqin Ban, M.S., Douglas Burger, PhD.. Evaluation of Humanized mouse as a means to identify the pathetic CD8 T cells causing human Type I diabetes (In preparation). 
12.	Guotong Man, MD, PhD, Vihas Patel, MD, Caryn Domenici Belisle, RPh, Stanley Ashley, MD. Administration and management of Total Parenteral Nutrition in patients complicated with septicemia. Manuscript in preparation. 
Conference Presentations
1.	Potential of ATL146e, an Adenosine Receptor Agonist, to Prevent Rejection of Xenogeneic Hematopoietic Cells and to Facilitate Xenotolerance Induction by Mixed Chimerism.  Transplantation Biology Research Center (TBRC), Surgery Department, Massachusetts General Hospital, Harvard Medical School, Harvard University, Boston, The United States, 2007.
2.	Induction of human T and B cell tolerance to pig islets through mixed chimerism in humanized NOD/SCID mice. Transplantation Biology Research Center (TBRC) , Surgery Department, Massachusetts General Hospital, Harvard Medical School, Harvard University, Boston, The United States, 2007.
3.	Initial investigation in using CD4 + NKT, alloantigen loaded DC, a-GalCer and blockade of NKG2d to prolong islet allograft. Presentation in laboratory meeting. Diabetes Institutes, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Harvard University. Cambridge, MA, The United States, 2006.
4.	Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Presentation in laboratory meeting. Diabetes Institutes, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Harvard University. Cambridge, MA, The United States, 2006.
5.	What can we do for DCs in vitro and in vivo to treat autoimmune disease and improve allograft prolongation?  Presentation in laboratory meeting. Diabetes Institutes, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Harvard University. Cambridge, MA, The United States, 2006.
6.	TH1 and TH2 Cells, Macrophages, Tc Cells, and NK Cells; Immunoregulation. Presentation in laboratory meeting. Diabetes Institutes, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Harvard University. Cambridge, MA, The United States, 2005.
7.	Functions of TH Cells. Presentation in laboratory meeting. Diabetes Institutes, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Harvard University. Cambridge, MA, The United States, 2005.
8.	DC & the initiation of immune responses. Presentation in laboratory meeting. Diabetes Institutes, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Harvard University. Cambridge, MA, The United States, 2005.
9.	Induction of human T-cell and tolerance to porcine xenoantigens through mixed hematopoietic chimerism. Transplantation Biology Research Center (TBRC) , Surgery Department, Massachusetts General Hospital, Harvard Medical School, Harvard University, Boston, The United States, 2004.
10.	Inhibition of human anti-pig cytotoxic lymphocytes by HLA expression in transgenic pig cells. Annual Academic Meeting of Beijing University, Beijing, China. 2003.
11.	Inhibition of hyperacute rejections in swine to human xenotransplantation In vitro model: expressing human CD59 proteins on pig and rat cells. 4th National Conference for Appraisal of Selective Papers by Young and Middle-aged Surgeons and 7th National Surgery Academic Conference. Qingdao, China, 1998.
12.	Investigation of contractility of gallbladder smooth muscle in gallbladder with cholelithiasis. 2nd China-Japan Gastrointestinal Tract Disease Academic Conference. Tianjing, China. 1993.
13.	Investigation of the contractile function in the patients with cholesterol stones or with pigment stones. 5th National Biliary Tract Surgery Meeting. Shanghai, China. 1993
14.	Investigation of contractility of gallbladder smooth muscle in gallbladder with cholelithiasis. National Medical Progress Seminars. Shanghai, 1992.

Reference:
Upon Request.